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Abstract
Rationale: Mutations in MYBPC3 encoding cardiac myosin binding protein C are common genetic cause of hereditary
cardiac myopathies. An intronic 25-bp deletion in MYBPC3 at 39 region is associated with dilated (DCM) and hypertrophic
(HCM) cardiomyopathies in Southeast Asia. However, the frequency of MYBPC3 25 bp deletion and associated clinical
presentation has not been established in an unrelated cohort of left ventricular dysfunction (LVD) secondary to coronary
artery disease (CAD) patients.
Objective: We sought to determine the role of MYBPC3 25 bp polymorphism on LVD in two cohorts of CAD patients.
Methods and Results: The study included 265 consecutive patients with angiographically confirmed CAD and 220 controls.
MYBPC3 25 bp polymorphism was determined by polymerase chain reaction. Our results showed that carrier status of
MYBPC3 25 bp deletion was associated with significant compromised left ventricle ejection fraction (LVEF #45) in CAD
patients (p value = ,0.001; OR=4.49). To validate our results, we performed a replication study in additional 140 cases with
similar clinical characteristics and results again confirmed consistent findings (p=0.029; OR=3.3). Also, presence of the gene
deletion did not have significant association in CAD patients with preserved ejection fraction (LVEF.45) (p value =0.1; OR
=2.3).
Conclusion: The frequency of MYBPC3 DW genotype and D allele was associated with compromised LVEF implying that
genetic variants of MYBPC3 encoding mutant structural sarcomere protein could increase susceptibility to left ventricular
dysfunction. Therefore, 25 bp deletion in MYBPC3 may represent a genetic marker for cardiac failure in CAD patients from
Southeast Asia.
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Introduction
Coronary artery disease (CAD) is defined as atherosclerotic
blockage[1] of arteries, supplying oxygen rich blood to the
myocardium (heart muscle), is the most common cause of fatality,
disability and economic loss, particularly in industrialized countries.
While the signs and symptoms of coronary artery disease are noted in
advanced state of disease, most individuals remain asymptomatic for
decades. Furthermore, major complication that some CAD patients
face over time is the development of Left Ventricle dysfunction (LVD).
The LVD usually leads to heart failure, arrhythmias and other
cardiovascular complications. Besides poorly developed collaterals,
extensive atherosclerotic disease and large myocardial infarction are
traditional predictors of LVD. However, in clinical practice, it is
observed that some CAD patients who do not have such
complications but still develop LVD, whereas others with well-defined
predictors do not develop LV dysfunction, which is quite puzzling.
Earlier genetic studies have correlated LVD with dilated
cardiomyopathy (DCM).[2] Mutations in several genes including
those encoding sarcomeric proteins such as myosin heavy polypep-
tide (MYH7), cardiac troponinI (TNNI3),[3] cardiac myosin binding
protein C (MYBPC3)[4] have been identified in DCM.[5,6,7]
Myosin-binding protein C (MyBP-C) is a key constituent of
cardiac muscle thick filaments, which by interacting with myo-
sin,[8,9,10] titin[11] and actin[12] contributes to the structural
integrity of the sarcomere and regulates cardiac contractility in
response to adrenergic stimulation.[13,14] Mutations in MYBPC3
result in disorganized sarcomeric structure, thus MYBPC3 has
emerged as an important gene for increased risk of heart failure
through cardiomyopathies (DCM and HCM).[15,16,17,18]
A common polymorphic intronic deletion of 25-base- pair in
MYBPC3 at the 39 region of the gene [19] has been recently
reported to be associated with DCM and HCM in populations of
Southeast Asia.[20] The deletion in intron 32 causes skipping of
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amino acids at C-terminal region of the protein.[19,20] The 25-bp
deletion is present in 2–6% of individuals in Indian populations
and high incidence of cardiac diseases has been partly attributed to
the existence of this polymorphism. Two community based studies
carried out in UK reported significant ethnic differences in left
ventricular systolic function and underlying CAD between South
Asians and European white subjects.[21,22] Moreover, a close
relation between LV ejection fraction (LVEF) and mortality has
also been demonstrated. Therefore, we carried out the present
study to assess if the common polymorphism in MYBPC3 has any
role in LV dysfunction. To the best of our knowledge, it is the first
study to report the association of 25 bp polymorphism of MYBPC3
with low left ventricular ejection fraction in CAD patients.
Results
1.1 Patient characteristics
Demographic and lipid profile of healthy subjects is shown in
Table 1. Clinical characteristics of CAD patients -Primary,
replication and combined cohorts of study are shown in Table 2.
In combined cohort, there was no significant difference in the
mean age of CAD patients and controls. The male/female ratio
was comparable in both CAD cases as well as in controls.
Evaluation of the defined risk factors in the cohort showed that
45.9% patients were hypertensive and 28.4% patients were
diabetic. Moreover, 26.4% patients were associated with smoking.
Patients with stable angina were 31.4% and unstable angina/ Non
ST Segment Elevation Myocardial Infarction (NSTEMI) formed
20.5% of the clinical syndrome. ST Segment Elevation Myocar-
dial Infarction (STEMI) patients with anterior wall myocardial
infarction (AWMI) and inferior wall myocardial infarction (IWMI)
were 28.1% and 19.5% respectively. Only two patients were found
to be affected with lateral wall myocardial infarction (LWMI)
(0.5%).The angiographic profile categorized patients with single
vessel disease (SVD), double vessel disease (DVD), and triple vessel
disease (TVD) as 68.9%, 24.7% and 6.4% respectively. The mean
ejection fraction was 50.0611.18. The kurtosis and skewness for
left ventricular ejection fraction (LVEF) were 0.12 and 20.98.
Thus, the data appeared to be normally distributed. We
considered #45% LVEF cut off as significant LVD. Of the total
405 CAD patients, 74.1% showed preserved (.45%) ejection
fraction while 25.9% had compromised ejection fractions (#45%)
and were categorized as having significant LVD. All the values in
primary stage matched to replication stage and there was no
significant difference in the values of three stages of the study.
1.2 Influence of MYBPC3 25 bp Deletion on CAD and its
clinical characteristics
Distributions of genotypes of MYBPC3 gene deletion in controls
were in accordance with Hardy-Weinberg equilibrium (p=0.98).
Considering the low allelic frequency allele, we also applied fisher
exact test for conditional probability of heterozygous variants
which was found to be p=0.97.
After this we compared the genotype and allele frequency of
MYBPC3 25 bp polymorphism between CAD patients (both stages)
and healthy controls. Our results suggested significant association of
MYBPC3 gene deletion with CAD [Table 3 (Primary; Replication);
DW genotype p value =0.03; ,0.01: D allele p value =0.03;
,0.01]. The frequency of MYBPC3 gene deletion in total (Primary
and replication cohorts) CAD patients was also significantly higher
(p value=0.003; Table 4) than healthy controls. As there were no
homozygous DD genotyped individuals in both cases and controls,
the heterozygous carrier (DW) itself associated with CAD.
Further, we compared the distribution of wild type (WW)
genotype of MYBPC3 (no deletion) and DW (Carrier of one deleted
allele) with clinical characteristics of CAD. There were no
significant differences between frequencies of WW and DW with
reference to clinical characteristics of CAD, except with compro-
mised LVEF (Table 5. 23.5% vs. 52.9%, p- value=,0.01) Also, a
borderline significance (p value ,0.05) was also observed in case of
triple vessel disease. When CAD patients were divided on the basis
of associated phenotypes like diabetes mellitus, hypertension or risk
factors like smoking status of the subjects carrying wild type and
deleted allele, the MYBPC3 gene deletion did not modulate the risk
of CAD due to these phenotypes or factors.
1.3 Influence of MYBPC3 25 bp Deletion on CAD patients
with reduced and preserved ejection fraction
In case-only analysis, first we applied linear model on all CAD
patients and found 25 bp gene deletion to be significantly
associated with compromised LVEF (p value = ,0.002
[B=6.3] Table 6). Then we segregated CAD patients on the
basis of compromised (,/=45%) and preserved (.45%) left
ventricular ejection fraction and compared with their status of
MYBPC3 gene polymorphism. We found that higher percentage of
CAD patients carrying heterogeneous DW genotype had com-
promised ejection fraction as compared to the patients with
preserved ejection fraction. This difference was statistically
significant (p value =0.004 OR =4.32 (1.58 – 11.82) Table 7).
In addition, we performed a replication study on 140 more CAD
patients and compared with primary cohort. The effect was
consistently stronger in the CAD patients with reduced ejection
fraction than CAD patients with preserved ejection fraction
subgroups (p value =0.029 OR=6.208 (3.3 (1.1–10.1)] Further-
more, we calculated the z and p values to look into the overall
significance and the results again confirmed the association of
25 bp gene deletion with compromised ejection fraction (Table 7).
We looked for the association of MYBPC3 gene deletion on
LVD by changing the cut off values for LVEF to ,40% and
,50% also. The level of significance decreased when we
considered the cut off for LV dysfunction to 50% and at 40%
cut off, level of significance increased but we would have missed
some patients with LV dysfunction. Therefore, we selected the cut
off to 45% to include definite patients with LV dysfunction.
1.4 Frequency Distribution of MYBPC3 25 bp deletion
polymorphism in CAD patients with preserved and
compromised LVEF and Controls
To further evaluate whether MYBPC3 gene deletion is associated
withCADorLVEF,weanalyzed the statusofgenedeletioninCAD
Table 1. Demographic and lipid profile of healthy subjects.
Number (n) =220
Age- yr6SD 54.9468.12
Male sex n (%) 173 (78%)
Lipid Levels
a) High Density Lipoprotein (mg/dl) 34.2962.62
b) Low Density Lipoprotein (mg/dl) 110.0068.68
c) Triglycerides (mg/dl) 154.46610.04
d) Total cholesterol (mg/dl) 163.2668.55
doi:10.1371/journal.pone.0024123.t001
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CAD patients, 105 CAD patients had ejection fraction #45 while
remaining 300 had preserved LVEF (.45). On comparing the
genotype frequency distribution of these two groups of patients with
that of healthy controls it was observed that only carriers of DW
genotype were associated with LVEF [DW genotype p value =
,0.001 OR =11.6 (3.9–34.2)]; D allele p value = ,0.001 [9.8
(3.5–27.6)] while no risk of DW genotype was observed in CAD
patients with preserved ejection fraction [Table 8; DW genotype p
value =0.09; OR=2.3 (0.8–6.6); D allele (p=0.1;OR=2.3
Table 2. Clinical Characteristics of CAD patients.
CLINICAL CHARACTERISTICS Primary Stage Replication Stage Combined
Total Subjects 265 140 405
*Age – yr 56.52610.20 54.3668.179 55.7869.59
Male sex 225 (84.9) 123 (87.9) 348 (85.9)
RISK FACTORS
Hypertension 119 (44.9) 67 (47.9) 186 (45.9)
Diabetes 77 (29.1) 38 (27.1) 115 (28.4)
Smoking 67 (25.3) 40 (28.6) 107 (26.4)
*Lipid Levels
a) High Density Lipoprotein (mg/dl) 32.3167.91 31.8865.86 32.1967.45
b) Low Density Lipoprotein (mg/dl) 100.13624.33 103.74622.90 100.97624.40
c) Triglycerides (mg/dl) 155.64669.19 125.41635.54 149.11662.25
d)Total cholesterol (mg/dl) 170.30621.98 141.75639.61 163.74630.53
CLINICAL SYNDROME
Stable angina 82 (30.9) 45 (32.1) 127 (31.4)
Unstable angina/Non ST Elevation Myocardial Infarction (NSTEMI) 59 (22.3) 24 (17.1) 83 (20.5)
ST Elevation Myocardial Infarction (STEMI) 124 (46.8) 71 (50.7) 195 (48.1)
Anterior wall myocardial infarction (AWMI) 72 (27.2) 42 (30) 114 (28.1)
Inferior wall myocardial infarction (IWMI) 51 (19.2) 28 (20) 79 (19.5)
Lateral wall myocardial infarction (LWMI) 1 (0.4) 1(0.7) 2 (0.5)
ANGIOGRAPHIC PROFILE
Single vessel disease (SVD) 165 (62.3) 114 (81.4) 279 (68.9)
Double vessel disease (DVD) 77 (29.1) 23 (16.4) 100 (24.7)
Triple vessel disease (TVD) 23 (8.7) 3 (2.1) 26 (6.4)
LEFT VENTRICULAR FUNCTION
*Mean Left Ventricle Ejection Fraction (LVEF) 50.70611.65 48.56610.2 50.0611.18
.45 206 (77.7) 94 (67.1) 300 (74.1)
#45 59 (22.3) 46 (32.9) 105 (25.9)
*Values are mean 6 SD.
doi:10.1371/journal.pone.0024123.t002
Table 3. Distributions for 25 bp deletion in MYBPC3 in CAD patients and Healthy controls.
Genotypes/
Allele
HC (220)
N( % )
CAD
a(265)
N( % )
CAD
b(140)
N( % )
p– value
a
OR (95% CI)
p– value
b
OR (95% CI)
WW 215 (97.7) 248 (93.6) 123 (87.9) 1(reference) 1(reference)
DW+DD 5 (2.3) 17 (6.4) 17 (12.1) 0.03 ; 3.0 (1.1–8.5) ,0.01 ; 6.8 (2.3–19.3)
W 435 (98.9) 513 (96.8) 263 (93.9) 1(reference) 1(reference)
D 5 (1.1) 17 (3.2) 17 (6.1) 0.03 ; 3.0 (1.0–8.2) ,0.01 ; 6.3 (2.2–17.5)
CAD-Coronary artery disease, HC-Healthy control, OR–Odds Ratio, CI–Confidence interval.
D, allele with deletion; W, wild-type allele;
aCAD patients in Primary cohort;
bCAD patients in Replication cohort.
a= represents the p value for the comparison of carriers (D,W + D,D) and non-carriers (W,W) in CAD patients (primary cohort) and HC.
b= represents the p value for the comparison of carriers (D,W + D,D) and non-carriers (W,W) in CAD patients (replication cohort) and HC.
Significant values are shown in BOLD.
doi:10.1371/journal.pone.0024123.t003
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deletion does not show any association with CAD patients having
preserved LVEF.
Generally,CADpatients withSTelevationMIaremore proneto
develop LV dysfunction which was also evident in the presentstudy.
Therefore, we looked for any significant interaction of STEMI with
MYBPC3 deletion status and low Ejection fraction but found
borderline significance (p value=0.04) whereas in case of CAD
patients with low LVEF and no history of STEMI, the association
with MYBPC3 gene deletion was highly significant (p val-
ue=0.001). It suggests that MYBPC3 gene deletion is influencing
development of LVD in CAD patients without history of STEMI.
Discussion
The main finding of the present study suggests close relationship
between the MYBPC3 25 bp polymorphic deletion, a common
MYBPC3 variant, and significantly higher risk of severe left
ventricular dysfunction (LVD) in CAD patients.
Notably, LVD is a complex condition that emerges as a
common pathway for a host of cardiac disorders. The LVD results
from the changes in the structure and function of heart muscle as
well as changes in collagen and other cardiac proteins.
Previously, a number of mutations in the genes for sarcomeric
proteins have been found to be associated with the risk of DCM [7]
and some of them are shown to cause sarcomeric disorganization,
which is believed as one ofthe mechanisms by which pathogenesisis
triggered in the heart.[8], [23] In addition to genetic predisposition,
viral infection, molecular mimicry, and oxidative stress are potential
contributing factors to dilated cardiomyopathy. These factors are
believed to be present before DCM and lead to severe LV
dysfunction. Individuals, who are genetically predisposed, when
exposed to any of these contributory factors, may develop LVD.
Similarly, we believe that CAD patients carrying the 25 bp
polymorphic deletion in MYBPC3 when triggered by severe
ischemic insult to the cardiac muscle cell (in place of viral
infection or other contributory factors for the development of
DCM) may be more likely to develop severe LV dysfunction in
comparison to CAD patients who are not carrying this mutation.
A large number of studies during last ten years have clearly
confirmed that cardiac myosin binding protein C plays pivotal role
in the genesis of cardiac muscle disorders.[20] The 25 bp intronic
deletion causes skipping of exon 33 and incorporation of mis-sense
of amino acids at the C-terminal.[19,20] The mutated protein has
been shown to incorporate in the myofibrils [20] and may cause
breakdown of sarcomere.
Several mechanisms have been proposed to explain pathogenesis
of cardiac muscle due to truncated and mis-sense myosin binding
protein C. These include poison peptides, haplo-insufficiency
caused by nonsense-mediated mRNA decay and impairment of
ubiquitin–proteasome system (UPS). The missense MYBPC3
mutations have been reported to destabilize its proteins through
UPS and it may contribute to cardiac dysfunction through
impairment of the ubiquitin-proteasome system.[24] It has been
shown that mutant cMyBP-C protein is preferentially degraded by
the ubiquitin proteasome system (UPS), which, in turn, may
competitively inhibit breakdown of other UPS substrates. Also,
takingintoconsideration the decline infunctionoftheUPSwith age
and oxidative stress [25,26] the altered protein may simply
accumulate, disrupt the cellular homeostasis and initiate LVD
A recent study from UK explored any ethnicity-related
differences in left ventricular function, structure and geometry in
a population based study of UK Indian Asian and European Whites
[22] and they observed significant differences in cardiac structure
and sensitive parameters of LV function. Earlier, another UK based
study didnot observe differencesinincidenceof LVSD butreported
that majority of patients originating from Indian subcontinent had
CADasunderlyingcauseofLVSD.[21]AsMYBPC325 bpdeletion
is mainly confined to Southeast Asia,[20] it is possible that some of
the differences in two groups (Southeast Asians and Whites) might
be associated with the common MYBPC3 25 bp deletion.
So far, the influence of 25 bp MYBPC3 intronic deletion on
LVD in patients with DCM was known.[27] However, our results
show that CAD patients with MYBPC3 25 bp deletion also
become more prone to LVD. Presently there are no such methods
or tests available to pinpoint CAD patients who are at higher risk
of developing severe cardiac disorder in later stages. The late onset
symptoms and influence of secondary risk factors may cause a
lasting threat to the carriers. However, the gene-based insights into
pathophysiology may allow more subtle clinical manifestations to
be identified and additional phenotypes associated with the variant
Table 4. Overall genotypic and allelic frequency of MYBPC3 in
total CAD patients.
Genotypes/
Allele
HC (220)
N( % )
CAD(405)
N( % )
p– value
OR (95% CI)
WW 215 (97.7) 371 (91.6) 1(reference)
DW 5 (2.3) 34 (8.4) 0.003 ; 4.3 (1.6–11.2)
W 435 (98.9) 776 (95.8) 1(reference)
D 5 (1.1) 34 (4.2) 0.003 ; 4.1 (1.5–10.6)
Significant values are shown in BOLD.
doi:10.1371/journal.pone.0024123.t004
Table 5. Effect of MYBPC3 deletion on clinical characteristics
in total CAD patients.
Variable
MYBPC3 (WW)
N =371 (%)
MYBPC3 (DW)
N =34 (%) P value
Stable Angina 113 (30.5) 14 (41.2) NS
Unstable Angina 54 (14.6) 3 (8.8) NS
Anterior wall Myocardial
Infarction
103 (27.8) 9 (26.5) NS
Inferior wall Myocardial
Infarction
71 (19.1) 8 (23.5) NS
Single Vessel Disease (SVD) 257 (69.3) 22 (64.7) NS
Double Vessel Disease (DVD) 93 (25.1) 7 (20.6) NS
Triple Vessel Disease (TVD) 21 (5.7) 5 (14.7) ,0.05
LVEF ,45 87 (23.5) 18 (52.9) ,0.01
Significant values are shown in BOLD; NS= Non-significant.
doi:10.1371/journal.pone.0024123.t005
Table 6. Parameter Estimate Applying General Linear Model.
All SubjectsWW DW+DD P-value
No of Subjects 405 371 34
LVEF 50.0611.1 50.5610.92 44.26612.5 ,0.002
Significant value is shown in BOLD.
doi:10.1371/journal.pone.0024123.t006
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identification of persons at risk of severe LV dysfunction and heart
failure among various Indian populations and migrants of Indian
origin. Thus, could be accompanied by appropriate medications
and advice for a lower-risk lifestyle.
Study limitations
The sample size in our present study is limited, therefore it will
require confirmation in larger cohorts. Because this is an
association study, we cannot rule out the presence of possible
linkage disequilibrium with other neighboring genes that might
explain the significant association with atherosclerotic phenotype
or adverse prognosis.
Moreover, it is a retrospective study, so it must also be carried
out prospectively before clinical application. Notably, the study
was conducted in patients with severe CAD undergoing
angioplasty and it is not certain whether the patients had LVD
before ischemic insult or the left ventricular dysfunction developed
later.
Conclusion
Our study suggests that MYBPC3 25 bp polymorphic deletion is
associated in CAD patients with compromised left ventricular
ejection fraction. It implies that a common genetic variant of
MYBPC3 encoding structural sarcomere protein could increase
susceptibility to left ventricular dysfunction, particularly following
an ischemic event. These findings add new evidence to existing
data on the linkage between MYBPC3 function and outcome in
patients in later stages in the cardiac failure. Therefore, the
MYBPC3 25 bp deletion may be explored as biomarker for the
development of severe LV dysfunction in CAD patients of persons
originating from Indian subcontinent.
Materials and Methods
Ethics Statement
The institutional ethical committee of Sanjay Gandhi Post
Graduate Institute of Medical Sciences (SGPGIMS) approved the
study protocol, and the authors followed the norms of World’s
Table 7. Distributions of 25 bp deletion in MYBPC3 in CAD patients with preserved (LVEF .45) and compromised (LVEF #45) Left
Ventricular ejection fraction.
Primary Stage
LVEF Categorical Genotypes
Total CAD
N (%) p– value OR (95% CI)
.45 WW 198 (96.1) - 1 (reference)
DW+DD 8 (3.9)
#45 WW 50 (84.7) ,0.001 4.32 (1.58–11.82)
DW+DD 9 (15.3)
Replication stage
LVEF Categorical Genotypes
Total CAD
N (%) p– value OR (95% CI)
.45 WW 86 (91.5) - 1 (reference)
DW+DD 8 (8.5)
#45 WW 37 (80.4) 0.029 3.3 (1.1–10.1)
DW+DD 9 (19.6)
Z overall 3.218.
P value ,0.001.
Significant values are shown in BOLD.
doi:10.1371/journal.pone.0024123.t007
Table 8. Frequency Distribution of MYBPC3 25 bp deletion polymorphism in CAD patients with preserved and reduced LVEF and
Controls.
Genotypes/
Allele HC (220) N (%)
CAD with preserved
LVEF (300) N (%)
CAD with reduced
LVEF (105) N (%)
p–value & OR (95% CI) for
CAD with preserved LVEF
a
p– value & OR (95% CI) for
CAD with reduced LVEF
b
WW 215 (97.7) 284 (94.7) 87 (82.9) 1(reference) 1(reference)
DW/DD 5 (2.3) 16 (5.3) 18 (17.1) 0.09 [2.3 (0.8–6.6)] ,0.001 [11.6 (3.9–34.2)]
W 435 (98.9) 584 (97.3) 192 (91.4) 1(reference) 1(reference)
D 5 (1.1) 16 (2.7) 18 (8.6) 0.1 [2.3 (0.8–6.4)] ,0.001 [9.8 (3.5–27.6)
D: allele with deletion; W: wild-type allele. Numbers in parentheses indicate the proportion of each genotype/allele as a percentage of total cases or controls. OR, odds
ratio for the likelihood CAD patients with preserved LVEF
a and reduced LVEF
b versus Healthy Controls (HC).
a= represents the p value for the comparison of carriers (D,W + D,D) and non-carriers (W,W) in CAD patients with preserved LVEF and HC.
b= represents the p value for the comparison of carriers (D,W + D,D) and non-carriers (W,W) in CAD patients with reduced LVEF and HC.
doi:10.1371/journal.pone.0024123.t008
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provided with written informed consent for the study.
2.1 Study Population
The present study was carried out in two stages, primary and
replication stages. In the primary stage, we studied 265 CAD
patients recruited from July 2008 to December 2009. In the
replication stage, further 140 cases were enrolled. The diagnostic
parameters used in the primary stage were also applied to the
replication stage
Both the primary and replication cohorts had significant
coronary artery disease, (diagnosis, confirmed by coronary
angiography and further all these subjects underwent coronary
angioplasty) recruited from the Department of Cardiology of
Sanjay Gandhi Postgraduate Institute of Medical Sciences
(SGPGIMS), Lucknow, Uttar Pradesh, India. The detailed clinical
history of CAD patients was based on hospital investigations
including angiography. Angiographically identified stenoses
.70% in the major coronary vessels at the time of the study
were used to classify patients as having single-vessel, double-vessel,
or triple-vessel disease.
The control (non-CAD) population consisted of 220 subjects
(173 males and 47 females) (mean age years 54.9468.12.) with no
clinical evidence of CAD or LV dysfunction (by echocardiography)
and also without positive family history of CAD or myocardial
infarction (MI). In addition, the inclusion criteria for controls were
absence of prior history of high systolic blood pressure, abnormal
lipid profile, diabetes mellitus and obesity. Both patient and
control were frequency-matched to age, gender and ethnicity.
After obtaining informed consent, all the individuals were
personally interviewed for information on food habits, occupation
and tobacco usage.
2.2 Data collection
The clinical data was obtained by reviewing the patient’s
medical records. Left ventricle ejection fraction (LVEF) was
calculated quantitatively by echocardiography, just before angi-
ography procedure, using the Simpson’s method.[28] Echocardi-
ography was repeated in 10% of patients and results were totally
concordant. Hypertension was defined as systolic blood pressure
.140 mmHg or a diastolic blood pressure .90 mmHg or patients
using antihypertensive drugs. Smoking was classified as smokers
(ex-smoker and current smokers) and non smokers. Similarly,
diabetes mellitus was defined as patients with fasting plasma
glucose .6.9 mmol/L or patients using anti-diabetic medication.
All laboratory parameters, as stated in the medical record, were
determined in fasting patients. Total cholesterol, high-density
lipoprotein (HDL) cholesterol and triglyceride levels were
measured by standard enzymatic methods. LDL cholesterol
concentrations were calculated using the Friedewald’s formu-
la.[29]
2.3 Genetic Analysis
Genomic DNA was isolated from peripheral blood leukocytes
according to a standard salting out method. [30] The polymor-
phism was genotyped using the polymerase chain reaction
method. As a negative control, PCR mix without DNA sample
was used to ensure contamination free PCR product. Laboratory
personnel were blinded to the case–control status of the subjects
and genotyping was done using a pair of primers [20] flanking the
25 bp deletion region in MYBPC3. PCR products (Wild Type
[WW]: 403 bp and mutant [DW]: 378 bp) were analysed on 6%
polyacrylamide gel. Ten percent of samples from patients and
controls were sequenced to evaluate the quality of genotyping,
which showed 100% concordance.
2.4 Statistical analysis
Descriptive statistics were presented as mean and standard
deviation (SD) for continuous measures while absolute value and
percentages were used for categorical measures. The chi-square
goodness of fit test was used for any deviation from Hardy
Weinberg Equilibrium in controls and fisher exact test was applied
as given by Emigh [31] Differences in genotype and allele
frequencies between study groups were estimated by chi-square
test. The ORs were adjusted for confounding factors such as age
and gender. In addition, the association between MYBPC3 25 bp
deletion and significant risk factors of CAD were analyzed using
binary logistic regression. Student t test was applied to find the
significance for plasma cholesterol. Differences between groups
stratified on the basis of genotypes were assessed using z
proportional test. Overall we performed meta analysis by Stouffers
method to combine the results of two cohorts (primary and
replication) to calculate the overall z and p values. A two-tailed p-
value of less than 0.05 was considered a statistical significant result.
All statistical analyses were performed using SPSS software version
16.0 (SPSS, Chicago, IL, USA).
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